By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA), announced the successful completion of a private placement transaction, generating approximately $8.7 million. The notes, bearing a 6.0% annual interest rate and maturing in July 2028, can be converted into Eterna common...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) announced positive Phase 1 clinical trial results for their investigational immunotherapeutic, UB-312, in Parkinson’s disease patients. The data showed that the antibodies effectively engage with aggregated alpha-synuclein, a toxic protein associated with PD,...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) said it plans to conduct a clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation for severe obstructive sleep apnea treatment. This follows positive preliminary data from a study that...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) announced the appointment of Brant Binder, a seasoned leader and entrepreneur with more than 25 years of strategic expertise building and growing biotechnology companies and Richard Wagner, Ph.D., a biotechnology entrepreneur with more than...

By Daniella Parra A recent survey by ProSomnus, Inc. (NASDAQ: OSA) and Proedge revealed that 71% of snorers have never sought medical advice. Obstructives Sleep Apnea (OSA) is a recurring airway collapse during sleep, linked to serious comorbidities. Over one...

By Daniella Parra Prenetics Global Limited (NASDAQ: PRE) and Prof. Dennis Lo, the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong have formed a joint venture named Insighta, aiming to revolutionize multi-cancer early detection screening....

By Daniella Parra Swiss life sciences company Lunaphore Technologies SA has agreed to be acquired by Bio-Techne Corporation, (NASDAQ:TECH) a global provider of tools and reagents for research and diagnostics. Lunaphore’s advanced microfluidic technology enables the analysis of biomarkers in...

By Daniella Parra Vaxxinity (Nasdaq: VAXX) has revealed encouraging findings from the Phase 1b clinical trial of UB-312, their vaccine candidate targeting alpha-synuclein for the treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies. The study demonstrated that UB-312...

By Daniella Parra HistoIndex will present advancements in AI-powered stain-free tissue imaging for NASH clinical trials at the EASL Congress 2023. “HistoIndex’s participation in the EASL Congress and the acceptance of our research partners’ 14 abstract submissions exemplify our unwavering...

By Daniella Parra Avertix Medical and AdventHealth Orlando have introduced the Guardian™ System, an FDA-approved implantable heart attack detection and warning system. “I believe the Guardian System introduces a significant advancement in cardiac care, potentially transforming how we detect heart...